Resveratrol and Huntington Disease (REVHD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02336633 |
Recruitment Status :
Completed
First Posted : January 13, 2015
Last Update Posted : February 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Huntington Disease | Dietary Supplement: Resveratrol Other: Placebo | Not Applicable |
Thanks to neuroimaging biomarkers already validated in HD and the newly identified metabolic brain biomarkers using 31P-MRS, we can test for a reduction in neurodegeneration among HD patients resulting from an improvement in brain energy profiles with resveratrol.
We plan to randomize 102 early affected HD patients (with a maximum of 120 included patients) in France (5≤UHDRS≤40) in a randomized, double-blind, controlled study. Patients will receive either resveratrol at 80 mg (n=51), or placebo (n=51) for 12 months. Clinical benefit will be respectively evaluated by UHDRS and neuropsychiatric questionnaires; biological tolerance will be evaluated by routine biochemical blood tests and plasma measurements of resveratrol, these three factors will be tested every three months.
The primary end-point will be the measure of the rate of caudate atrophy - the most sensitive biomarker identified to date in HD - after one year of treatment with resveratrol in early affected HD patients using volumetric MRI as we described.
Secondary end-points include:
The clinical and biological tolerance of resveratrol in HD patients will be evaluated by (i) neuropsychiatric questionnaires: Starkstein apathy scale, Hospital Anxiety and Depression Scale (HADS), Systems Behaviour Inventory (FrSBe) and SF36, (ii) a cognitive test; Symbol Digit Modalities Test (SDMT) and (iii) routine biochemical tests The clinical benefit of resveratrol will be evaluated by a decrease in the progression of the UHDRS over a year of treatment The benefit of resveratrol on brain energy metabolism will be evaluated by the restoration of an increased ratio of inorganic phosphate/phosphocreatine - reflecting normal brain activation - during visual stimulation, using 31P-MRS as we described The progression of caudate atrophy over a year will be correlated with the changes in brain energy profile as well as changes in the progression of the UHDRS.
The compliance of treatment and peak in plasmatic concentration through plasma measurements of resveratrol.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 102 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Metabolic Intervention Using Resveratrol in Patients With Huntington Disease |
Study Start Date : | July 2015 |
Actual Primary Completion Date : | October 2019 |
Actual Study Completion Date : | January 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Resveratrol (80mg/j = 4 capsules/day)
|
Dietary Supplement: Resveratrol
2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year |
Placebo Comparator: 2
Placebo (4 capsules/day)
|
Other: Placebo |
- rate of caudate atrophy [ Time Frame: 1 year ]Measurement of the rate of caudate atrophy before and after one year of treatment with resveratrol in early affected HD patients using volumetric MRI.
- UHDRS (Unified Huntington Disease Rating Scale) [ Time Frame: 1 year ]
- TFC (Total Functional Capacity) [ Time Frame: 1 year ]
- ratio of inorganic phosphate/phosphocreatine [ Time Frame: 1 year ]The benefit of resveratrol on brain energy metabolism will be evaluated by the restoration of an increased ratio of inorganic phosphate/phosphocreatine - reflecting normal brain activation - during visual stimulation, using 31P-MRS will be assessed before and after 1 year of treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria :
- Positive genetic test with CAG repeat length > or = 39 in HTT gene
- At least 18 years of age
- Signature of the informed consent
- Covered by social security
- UHDRS score between 5 and 40 (both included)
- Ability to undergo MRI scanning
Exclusion criteria :
- Hypersensitivity to resveratrol or to one of its excipients (gelatin and glycerin)
- Tetrabenazine treatment
- Neuroleptic treatments other than olanzapine at small doses (≤10 mg) and Abilify® (≤15mg)
- VKA treatment (Previscan®, Sintron®, Coumadine®)
- NACO treatment (Pradaxa®, Xarelto®, Eliquis®)
- Additional psychiatric or neurological conditions
- Severe head injury
- Participation in another therapeutic trial (3 months exclusion period)
- Pregnancy and breastfeeding
- Inability to understand information about the protocol
- Persons deprived of their liberty by judicial or administrative decision
- Adult subject under legal protection or unable to consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336633
France | |
Institut du Cerveau et de la Moelle, Hôpital de la Pitié Salpêtrière | |
Paris, France, 75013 |
Principal Investigator: | Fanny Mochel, MD, PhD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT02336633 |
Other Study ID Numbers: |
P130918 |
First Posted: | January 13, 2015 Key Record Dates |
Last Update Posted: | February 5, 2020 |
Last Verified: | August 2019 |
Huntington disease Neurodegenerative disease Volumetric MRI |
31P MR spectroscopy metabolism Caudate atrophy |
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Dementia Chorea Dyskinesias Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |
Genetic Diseases, Inborn Cognition Disorders Neurocognitive Disorders Mental Disorders Resveratrol Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Enzyme Inhibitors Platelet Aggregation Inhibitors |